BridgeMD
New treatment option for Liver Cancer
Official title DEB-TACE Prior to Liver Transplantation in the Treatment of HCC
ClinicalTrials.gov ID: NCT06353126
What this study is testing
- What it's testing
- The goal of the study is to explore whether the usage of DEB-TACE (Drug-Eluting Bead Transarterial Chemoembolization) prior to living donor liver transplantation can prolong the recurrence-free survival in patients with hepatocellular carcinoma (HCC). It is a single-center, exploratory study.
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Age 18-75 years;
- people with viral hepatitis or cirrhosis are clinically diagnosed according to AASLD standards, which require a history of viral hepatitis or...
- Child-Pugh score A-B grade;
- Tumor present in the right lobe of the liver;
- Liver cancer assessment meeting the "up to seven" criteria: the sum of tumor size and number does not exceed 7;
You likely can't join if
- Presence of definite cancer thrombi in the main portal vein, vena cava, or main bile duct;
- Severe hepatic encephalopathy;
- Coexisting pulmonary arterial hypertension (moderate to high risk, WHO Grade III-IV);
- Severe contrast agent allergy;
- Irreversible hepatic artery to hepatic vein shunt;
- Special types of anatomical variations (Asan portal vein type III);
See the full eligibility criteria
- Age 18-75 years;
- people with viral hepatitis or cirrhosis are clinically diagnosed according to AASLD standards, which require a history of viral hepatitis or cirrhosis combined with imaging examinations (enhanced CT, MRI...
- Child-Pugh score A-B grade;
- Tumor present in the right lobe of the liver;
- Liver cancer assessment meeting the "up to seven" criteria: the sum of tumor size and number does not exceed 7;
- ECOG-PS score 0-1;
- Scheduled for living donor liver transplantation as the primary treatment;
- Signed informed consent form.
- Presence of definite cancer thrombi in the main portal vein, vena cava, or main bile duct;
- Severe hepatic encephalopathy;
- Coexisting pulmonary arterial hypertension (moderate to high risk, WHO Grade III-IV);
- Severe contrast agent allergy;
- Irreversible hepatic artery to hepatic vein shunt;
- Special types of anatomical variations (Asan portal vein type III);
- Extrahepatic metastatic tumors;
- Concurrent active hepatitis or severe infection;
- Tumor dissemination or distant metastasis, expected survival \<3 months;
- Renal dysfunction, creatinine \>176.8 umol/L or creatinine clearance rate \<30ml/min;
- White blood cell count \<3.0x109/L, platelet count \<50x106/L, and unable to correct;
- Inability to tolerate surgical anesthesia (severe infection, cardiopulmonary insufficiency, cerebrovascular disease);
- Severe psychiatric illness;
- Other reasons deemed unsuitable for participation by the investigator.
The study team makes the final eligibility decision.
Where it's taking place
- Shanghai, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Shanghai, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.